Health and Fitness Health and Fitness
Mon, August 16, 2010
Fri, August 13, 2010

German District Court Finds RENASYSa" GO NPWT System Non-infringing


Published on 2010-08-13 12:30:46 - Market Wire
  Print publication without navigation


German District Court Finds RENASYS? GO NPWT System Non-infringing -- SCHENEFELD, Germany, Aug. 13 /PRNewswire-FirstCall/ --

German District Court Finds RENASYS? GO NPWT System Non-infringing

SCHENEFELD, Germany, Aug. 13 /PRNewswire-FirstCall/ -- The Advanced Wound Management division of Smith & Nephew Inc., a subsidiary of Smith & Nephew plc. (LSE: SN; NYSE: [ SNN ]) today announced that the German District Court in Mannheim has ruled in its favor in the RENASYS GO patent litigation case brought by Kinetic Concepts Inc. (NYSE: KCI). In this case, the Court has found that the Smith & Nephew RENASYS GO Negative Pressure Wound Therapy (NPWT) System, including its wound dressings, tubings, canisters and pumps, do not infringe on KCI's German patent EP 0 853 950 B1.

"We welcome the District Court's ruling with respect to our well known RENASYS GO NPWT System," said Robin Carlstein, Senior Vice President of Advanced Wound Devices at Smith & Nephew. "Germany is an important market for Smith & Nephew and we believe that this decision ultimately benefits patients and clinicians in Germany, who will be able to choose from our wide and dynamic NPWT offering when tailoring treatment."

Additionally, the Court ruled that specific features of the RENASYS EZ system – in particular one of its canisters when used with this device – infringes KCI's German patent EP 0 853 950 B1. This product represents a very small portion of the Smith & Nephew NPWT portfolio in Germany. The company will make appropriate modifications to this system as soon as possible in order to ensure that future sales of the RENASYS EZ system are not affected by this specific German KCI patent.  

The German patent EP 0853 950 B1 subject in the current court decision is still subject to a proceeding Nullity action in Germany brought against it by Smith & Nephew, where Smith & Nephew is arguing that the patent is not valid.

The RENASYS system enables clinicians to tailor NPWT to meet their patients' unique needs and the specific requirements of their wounds, with clear improvements in patient comfort, ease of use and cost-effectiveness.

For more information about Smith & Nephew, please visit [ www.smith-nephew.com ].

Inquiries




Investors


Liz Hewitt

+44 (0)20 7401 7646

Phil Cowdy


Smith & Nephew




Press


Justine McIlroy

+44 (0)20 7404 5959

Brunswick Group – London


Felipe Ucros

+212-333-3810

Brunswick Group – New York




Other inquiries


Robin Carlstein

+1 727 399 3766

Senior Vice President


Smith & Nephew Advanced Wound Devices



Markus Sebastian

+49 (0)40 879 744 100

General Manager    


Smith & Nephew Advanced Wound Management



About Smith & Nephew

Smith & Nephew is a global medical technology business with global leadership positions in Orthopaedics; including Reconstruction, Trauma and Clinical Therapies; Sports Medicine; and Advanced Wound Management.

Smith & Nephew is dedicated to helping improve people's lives.  The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust.  The Company operates in 32 countries around the world.  Annual sales in 2009 were nearly $3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995.  In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline.  These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements.  Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.  Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof.  All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing.  Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

<> Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.

SOURCE Smith & Nephew Inc.

[ Back to top ]

RELATED LINKS
[ http://www.smith-nephew.com ]

  • [ Share with Facebook ]
  • [ ]
  • [ Share with LinkedIn ]
  • [ Share with Buzz it ]

Other News Releases in Health Care & Hospitals

[ Technique to Preserve Fertility in Young Women May Be Unsafe for Patients With Leukemia ]

[ Tip Sheet: The World's Leading Aesthetic Plastic Surgeons Convene in San Francisco ]

[ Mylan Announces Completion of Add-On Offering of Senior Notes ]

Other News Releases in Patent Law

[ U.S. District Court Rules Against Lilly Regarding Strattera Patent ]

[ Sandata Technologies Acquires Medical Management Technology Group's Home Healthcare Customers ]

[ Halozyme Announces Issuance of U.S. Patent for rHuPH20 Enzyme Platform ]

Journalists and Bloggers

Visit [ PR Newswire for Journalists ] for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on [ The Digital Center ].

Contributing Sources